Company Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.
The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations.
The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer.
Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Barbara Weber |
Contact Details
Address: 201 Brookline Avenue, Suite 901 Boston, Massachusetts 02215 United States | |
| Phone | 857 320 4900 |
| Website | tangotx.com |
Stock Details
| Ticker Symbol | TNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819133 |
| CUSIP Number | 87583X109 |
| ISIN Number | US87583X1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barbara L. Weber M.D. | President, Chief Executive Officer and Director |
| Dr. Adam S. Crystal M.D., Ph.D. | President of Research and Development |
| Dr. Alan Ashworth FRS, Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. William G. Kaelin Jr., M.D. | Founder and Member of Scientific Advisory Board |
| Dr. Antoni Ribas M.D., Ph.D. | Founder and Member of Scientific Advisory Board |
| Timothy Redfern | Chief Financial Officer |
| Dr. Michael Palmieri Ph.D. | Head of Technical Operations |
| Jannik N. Andersen Ph.D. | Chief Scientific Officer |
| Douglas J. Barry Esq., J.D. | Chief Legal Officer, Chief Compliance Officer and Corporate Secretary |
| Julie Carretero | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 2, 2025 | SCHEDULE 13D/A | Filing |
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Nov 20, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 6, 2024 | 144 | Filing |